Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Targeting Ras in myeloid leukemias.

Braun BS, Shannon K.

Clin Cancer Res. 2008 Apr 15;14(8):2249-52. doi: 10.1158/1078-0432.CCR-07-1005. Review.

PMID:
18413813
[PubMed - indexed for MEDLINE]
Free Article
2.

Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.

Parikh C, Subrahmanyam R, Ren R.

Blood. 2006 Oct 1;108(7):2349-57. Epub 2006 Jun 8.

PMID:
16763213
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.

Parikh C, Subrahmanyam R, Ren R.

Cancer Res. 2007 Aug 1;67(15):7139-46.

PMID:
17671181
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Mouse model for NRAS-induced leukemogenesis.

Parikh C, Ren R.

Methods Enzymol. 2008;439:15-24. doi: 10.1016/S0076-6879(07)00402-8.

PMID:
18374153
[PubMed - indexed for MEDLINE]
5.

Ras processing as a therapeutic target in hematologic malignancies.

Le DT, Shannon KM.

Curr Opin Hematol. 2002 Jul;9(4):308-15. Review.

PMID:
12042705
[PubMed - indexed for MEDLINE]
6.

Differential oncogenic potential of activated RAS isoforms in melanocytes.

Whitwam T, Vanbrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, Koo HM, Holmen SL.

Oncogene. 2007 Jul 5;26(31):4563-70. Epub 2007 Feb 5.

PMID:
17297468
[PubMed - indexed for MEDLINE]
7.

Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.

Lauchle JO, Braun BS, Loh ML, Shannon K.

Pediatr Blood Cancer. 2006 May 1;46(5):579-85. Review.

PMID:
16261595
[PubMed - indexed for MEDLINE]
8.

The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.

Rotblat B, Ehrlich M, Haklai R, Kloog Y.

Methods Enzymol. 2008;439:467-89. doi: 10.1016/S0076-6879(07)00432-6.

PMID:
18374183
[PubMed - indexed for MEDLINE]
9.

Ras signaling and therapies.

Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F.

Adv Cancer Res. 2009;102:1-17. doi: 10.1016/S0065-230X(09)02001-6. Review.

PMID:
19595305
[PubMed - indexed for MEDLINE]
10.

Network analysis of oncogenic Ras activation in cancer.

Stites EC, Trampont PC, Ma Z, Ravichandran KS.

Science. 2007 Oct 19;318(5849):463-7.

PMID:
17947584
[PubMed - indexed for MEDLINE]
Free Article
11.

Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation.

Raepple D, von Lintig F, Zemojtel T, Duchniewicz M, Jung A, Lübbert M, Boss GR, Scheele JS.

Ann Hematol. 2009 Apr;88(4):319-24. doi: 10.1007/s00277-008-0593-6. Epub 2008 Sep 11.

PMID:
18784923
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Explaining the preponderance of Kras mutations in human cancer: An isoform-specific function in stem cell expansion.

Quinlan MP, Settleman J.

Cell Cycle. 2008 May 15;7(10):1332-5. Epub 2008 Mar 11.

PMID:
18418066
[PubMed - indexed for MEDLINE]
Free Article
13.

Targeting oncogenic Ras signaling in hematologic malignancies.

Ward AF, Braun BS, Shannon KM.

Blood. 2012 Oct 25;120(17):3397-406. doi: 10.1182/blood-2012-05-378596. Epub 2012 Aug 16. Review.

PMID:
22898602
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The Ras signaling pathway and the molecular basis of myeloid leukemogenesis.

Shannon K.

Curr Opin Hematol. 1995 Jul;2(4):305-8. Review. No abstract available.

PMID:
9372012
[PubMed - indexed for MEDLINE]
15.

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, Tamura A, Honda H, Sakata-Yanagimoto M, Kumano K, Oda H, Yamagata T, Takita J, Gotoh N, Nakazaki K, Kawamata N, Onodera M, Nobuyoshi M, Hayashi Y, Harada H, Kurokawa M, Chiba S, Mori H, Ozawa K, Omine M, Hirai H, Nakauchi H, Koeffler HP, Ogawa S.

Nature. 2009 Aug 13;460(7257):904-8. doi: 10.1038/nature08240. Epub 2009 Jul 20.

PMID:
19620960
[PubMed - indexed for MEDLINE]
16.

ras proteins and the ras-related signal transduction pathway.

Janowski M.

Radiat Environ Biophys. 1991;30(3):185-9. Review.

PMID:
1924703
[PubMed - indexed for MEDLINE]
17.

Interactions of Ras proteins with the plasma membrane and their roles in signaling.

Eisenberg S, Henis YI.

Cell Signal. 2008 Jan;20(1):31-9. Epub 2007 Aug 21. Review.

PMID:
17888630
[PubMed - indexed for MEDLINE]
18.

Endogenous K-ras signaling in erythroid differentiation.

Zhang J, Lodish HF.

Cell Cycle. 2007 Aug 15;6(16):1970-3. Epub 2007 Jun 10.

PMID:
17721087
[PubMed - indexed for MEDLINE]
Free Article
19.

Deregulated Ras signaling in developmental disorders: new tricks for an old dog.

Schubbert S, Bollag G, Shannon K.

Curr Opin Genet Dev. 2007 Feb;17(1):15-22. Review.

PMID:
17208427
[PubMed - indexed for MEDLINE]
20.

Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells.

Espino PS, Pritchard S, Heng HH, Davie JR.

Int J Cancer. 2009 Feb 1;124(3):562-7. doi: 10.1002/ijc.23959.

PMID:
19004007
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk